Ghost Tree Capital’s Mirati Therapeutics MRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
– Sell
-60,000
Closed -$2.61M – 87
2023
Q3
$2.61M Sell
60,000
-140,000
-70% -$5M 0.86% 41
2023
Q2
$7.23M Buy
200,000
+60,000
+43% +$2.47M 2.39% 16
2023
Q1
$5.2M Sell
140,000
-60,000
-30% -$2.7M 1.54% 27
2022
Q4
$9.06M Buy
200,000
+25,000
+14% +$1.62M 3.87% 11
2022
Q3
$12.2M Buy
175,000
+65,000
+59% +$4.81M 3.43% 10
2022
Q2
$7.38M Buy
110,000
+90,000
+450% +$5.72M 3.85% 9
2022
Q1
$1.64M Sell
20,000
-10,000
-33% -$1.02M 0.36% 37
2021
Q4
$4.4M Sell
30,000
-30,000
-50% -$4.66M 1.58% 25
2021
Q3
$10.6M Buy
60,000
+10,000
+20% +$1.61M 3.1% 10
2021
Q2
$8.08M Hold
50,000
– – 2.22% 14
2021
Q1
$8.56M Hold
50,000
– – 2.01% 17
2020
Q4
$11M Sell
50,000
-10,000
-17% -$2.16M 2.45% 18
2020
Q3
$10M Sell
60,000
-95,000
-61% -$13M 2.88% 9
2020
Q2
$17.7M Buy
155,000
+40,000
+35% +$3.88M 4.67% 6
2020
Q1
$8.84M Sell
115,000
-35,000
-23% -$3.14M 2.34% 15
2019
Q4
$19.3M Sell
150,000
-125,000
-45% -$12.1M 3.68% 6
2019
Q3
$21.4M Sell
275,000
-60,000
-18% -$5.63M 5.46% 4
2019
Q2
$34.5M Buy
335,000
+185,000
+123% +$14.4M 7.16% 5
2019
Q1
$11M Sell
150,000
-250,000
-63% -$17M 2.87% 13
2018
Q4
$17M Sell
400,000
-35,300
-8% -$1.41M 6.16% 2
2018
Q3
$20.5M Sell
435,300
-64,700
-13% -$3.6M 4.36% 4
2018
Q2
$24.6M Buy
500,000
+237,500
+90% +$8.97M 7.25% 2
2018
Q1
$8.06M Sell
262,500
-337,500
-56% -$9.37M 1.63% 19
2017
Q4
$11M Buy
+600,000
New +$9.31M 2.57% 12
2017
Q2
– Sell
-172,184
Closed -$895K – 79
2017
Q1
$895K Hold
172,184
– – 0.17% 60
2016
Q4
$818K Sell
172,184
-102,816
-37% -$559K 0.2% 65
2016
Q3
$1.82M Buy
275,000
+200,000
+267% +$1.06M 0.29% 69
2016
Q2
$410K Sell
75,000
-175,000
-70% -$2.79M 0.12% 60
2016
Q1
$5.35M Hold
250,000
– – 3.03% 13
2015
Q4
$7.9M Buy
+250,000
New +$8.83M 3.23% 11

Other funds holding MRTX

Ghost Tree Capital's MRTX Position: Q4 2023 in Review

Ghost Tree Capital sold out of Mirati Therapeutics (MRTX) in Q4 2023, closing a stake of 60,000 shares — an estimated $2.61M sold.

Ghost Tree Capital first reported a position in MRTX in Q4 2015 and held it in 30 quarters. The position peaked at $34.5M in Q2 2019. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Ghost Tree Capital reported no remaining Mirati Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Ghost Tree Capital sold 60,000 Mirati Therapeutics shares in Q4 2023, an estimated $2.61M.
  • Ghost Tree Capital first reported a position in Mirati Therapeutics in Q4 2015 and held it in 30 quarters.
  • Ghost Tree Capital's Mirati Therapeutics position peaked at $34.5M in Q2 2019.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics as of Q4 2023.

Based on Ghost Tree Capital's 13F filing for Q4 2023, filed 14 Feb 2024.